Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
Authors
Keywords
-
Journal
Biomolecules
Volume 12, Issue 11, Pages 1629
Publisher
MDPI AG
Online
2022-11-04
DOI
10.3390/biom12111629
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials
- (2022) Jeffrey S Heier et al. LANCET
- The changing landscape for the management of patients with neovascular AMD: brolucizumab in clinical practice
- (2022) Ian Pearce et al. EYE
- Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2022) Junyeop Lee et al. Journal of Clinical Medicine
- Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration
- (2022) Margaret A. Chang et al. JAMA Ophthalmology
- Angiopoietin/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data
- (2021) Antonia M. Joussen et al. EYE
- Inflammatory Complications of Intravitreal Anti-VEGF Injections
- (2021) Jacob T. Cox et al. Journal of Clinical Medicine
- Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study
- (2021) Louisa Maria Bulirsch et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes
- (2021) Jeffrey S. Heier et al. JAMA Ophthalmology
- Anti-VEGF-Resistant Retinal Diseases: A Review of the Latest Treatment Options
- (2021) Josh O. Wallsh et al. Cells
- Real-World Experience with Brolucizumab in Wet Age-Related Macular Degeneration: The REBA Study
- (2021) Alper Bilgic et al. Journal of Clinical Medicine
- Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
- (2021) Alper Bilgic et al. Journal of Clinical Medicine
- Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- (2021) Nancy M. Holekamp et al. OPHTHALMOLOGY
- Efficacy and Safety of Abicipar in Neovascular Age-Related Macular Degeneration
- (2020) Derek Kunimoto et al. OPHTHALMOLOGY
- Comparison of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
- (2020) Tock H. Lim et al. JAMA Ophthalmology
- THE ANGIOPOIETIN/TIE PATHWAY IN RETINAL VASCULAR DISEASES
- (2020) Jeffrey S. Heier et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Two-Year Results of the Phase 3 Randomized Controlled Study of Abicipar in Neovascular Age-Related Macular Degeneration
- (2020) Rahul N. Khurana et al. OPHTHALMOLOGY
- The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
- (2019) Peter A. Campochiaro et al. OPHTHALMOLOGY
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
- (2019) Pravin U. Dugel et al. OPHTHALMOLOGY
- A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration
- (2019) James T. Handa et al. Nature Communications
- Real-World Vision in Age-Related Macular Degeneration Patients Treated with Single Anti–VEGF Drug Type for 1 Year in the IRIS Registry
- (2018) Prethy Rao et al. OPHTHALMOLOGY
- The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration—A cost-effectiveness analysis from a societal perspective
- (2018) Freekje van Asten et al. PLoS One
- Real-World Results of Aflibercept versus Ranibizumab for the Treatment of Exudative AMD Using a Fixed Regimen
- (2018) Joana Providência et al. Biomed Research International
- A Phase 1, Open-Label, Dose-Escalation Trial to Investigate Safety and Tolerability of Single Intravitreous Injections of ICON-1 Targeting Tissue Factor in Wet AMD
- (2018) John A. Wells et al. Ophthalmic Surgery Lasers & Imaging Retina
- Safety and Efficacy of Anti-Vascular Endothelial Growth Factor Therapies for Neovascular Age-Related Macular Degeneration
- (2018) Sophie J. Bakri et al. OPHTHALMOLOGY
- Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular Degeneration
- (2018) David Callanan et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
- Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration
- (2017) Rehan M Hussain et al. EXPERT OPINION ON EMERGING DRUGS
- Photodynamic therapy: current role in the treatment of chorioretinal conditions
- (2016) D K Newman EYE
- Comparing the Effectiveness of Bevacizumab to Ranibizumab in Patients with Exudative Age-Related Macular Degeneration. The BRAMD Study
- (2016) A. M. E. Schauwvlieghe et al. PLoS One
- Ranibizumab for the treatment of wet AMD: a summary of real-world studies
- (2015) V Chong EYE
- Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration
- (2015) Charles C. Wykoff et al. OPHTHALMOLOGY
- Comparison of Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration According to LUCAS Treat-and-Extend Protocol
- (2015) Karina Berg et al. OPHTHALMOLOGY
- A randomized trial to compare the safety and efficacy of two ranibizumab dosing regimens in a Turkish cohort of patients with choroidal neovascularization secondary to AMD
- (2014) Bora M. Eldem et al. ACTA OPHTHALMOLOGICA
- Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration
- (2014) Stefano Piermarocchi et al. ACTA OPHTHALMOLOGICA
- Treatment of Exudative Age-Related Macular Degeneration with a Designed Ankyrin Repeat Protein that Binds Vascular Endothelial Growth Factor: a Phase I/II Study
- (2014) Eric H. Souied et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA)
- (2014) Ursula Schmidt-Erfurth et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
- (2014) Frank G Holz et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- One-Year Outcome of Ranibizumab for Neovascular Age-Related Macular Degeneration: A Thorough Analysis in a Real-World Clinical Setting
- (2014) Andrea Gabai et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes
- (2014) Meidong Zhu et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Effects of vitreomacular adhesion on ranibizumab treatment in Japanese patients with age-related macular degeneration
- (2014) Yoko Nomura et al. JAPANESE JOURNAL OF OPHTHALMOLOGY
- Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature
- (2014) Jikui Shen et al. JOURNAL OF CLINICAL INVESTIGATION
- A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study
- (2014) Sergio Pagliarini et al. Journal of Ophthalmology
- A three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outs
- (2013) Christina I. Frennesson et al. ACTA OPHTHALMOLOGICA
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
- (2013) Usha Chakravarthy et al. LANCET
- Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up
- (2013) Wataru Matsumiya et al. BMC Ophthalmology
- Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany
- (2012) Robert P. Finger et al. ACTA OPHTHALMOLOGICA
- Long-term effects of ranibizumab treatment delay in neovascular age-related macular degeneration
- (2012) Philipp S. Muether et al. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
- Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-Related Macular Degeneration
- (2012) Peter K. Kaiser et al. OPHTHALMOLOGY
- Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
- (2012) Daniel F. Martin et al. OPHTHALMOLOGY
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
- (2012) Jeffrey S. Heier et al. OPHTHALMOLOGY
- EVEREST STUDY
- (2012) Adrian Koh et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE
- (2012) Salomon Y. Cohen et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Medicare Costs for Neovascular Age-Related Macular Degeneration, 1994–2007
- (2011) Shelley Day et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
- (2011) C H Meyer et al. EYE
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Primary Endpoint Results of a Phase II Study of Vascular Endothelial Growth Factor Trap-Eye in Wet Age-related Macular Degeneration
- (2011) David M. Brown et al. OPHTHALMOLOGY
- Safety and Efficacy of a Flexible Dosing Regimen of Ranibizumab in Neovascular Age-Related Macular Degeneration: The SUSTAIN Study
- (2011) Frank G. Holz et al. OPHTHALMOLOGY
- A SYSTEMATIC REVIEW OF THE ADVERSE EVENTS OF INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR INJECTIONS
- (2011) Margriet I Van der Reis et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study
- (2011) Lars Hjelmqvist et al. Journal of Ophthalmology
- Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinician-determined retreatment strategy
- (2010) A. Kumar et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study
- (2010) Ursula Schmidt-Erfurth et al. OPHTHALMOLOGY
- A Variable-dosing Regimen with Intravitreal Ranibizumab for Neovascular Age-related Macular Degeneration: Year 2 of the PrONTO Study
- (2009) Geeta A. Lalwani et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
- Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial
- (2009) Peter K. Kaiser et al. CURRENT MEDICAL RESEARCH AND OPINION
- A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
- (2009) David S. Boyer et al. OPHTHALMOLOGY
- Ranibizumab Combined With Verteporfin Photodynamic Therapy in Neovascular Age-related Macular Degeneration (FOCUS): Year 2 Results
- (2008) Andrew N. Antoszyk et al. AMERICAN JOURNAL OF OPHTHALMOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now